Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 14, 2014 - Issue 5
Submit an article Journal homepage
431
Views
7
CrossRef citations to date
0
Altmetric
Drug Profiles

The cost–effectiveness of infliximab in Crohn’s disease

Claire SmartGastroenterology, Leeds Teaching Hospitals NHS Trust, Beckett Lane, Leeds, LS9 7TF, UK
&
Christian P SelingerCorrespondence[email protected]
Pages 589-598 | Published online: 20 Aug 2014

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Pochamana Phisalprapa, Chayanis Kositamongkol, Julajak Limsrivilai, Satimai Aniwan, Phunchai Charatcharoenwitthaya, Pises Pisespongsa, Taya Kitiyakara, Suporn Treepongkaruna & Nathorn Chaiyakunapruk. (2020) Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand. Journal of Medical Economics 23:11, pages 1302-1310.
Read now

Articles from other publishers (6)

Johan Burisch, Mirabella Zhao, Selwyn Odes, Peter De Cruz, Severine Vermeire, Charles N Bernstein, Gilaad G Kaplan, Dana Duricova, Dan Greenberg, Hans O Melberg, Mamoru Watanabe, Hyeong Sik Ahn, Laura Targownik, Valérie E H Pittet, Vito Annese, KT Park, Konstantinos H Katsanos, Marte L Høivik, Zeljko Krznaric, María Chaparro, Edward V LoftusJrJr, Peter L Lakatos, Javier P Gisbert, Willem Bemelman, Bjorn Moum, Richard B Gearry, Michael D Kappelman, Ailsa Hart, Marieke J Pierik, Jane M Andrews, Siew C Ng, Renata D'Inca & Pia Munkholm. (2023) The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology & Hepatology 8:5, pages 458-492.
Crossref
Naazish S. Bashir, Avery Hughes & Wendy J. Ungar. (2023) Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review. MDM Policy & Practice 8:1.
Crossref
Sunanda V. Kane. (2020) Preventing Perianal Disease. JAMA Network Open 3:6, pages e208041.
Crossref
Lachaine Jean, Miron Audrey, Catherine Beauchemin & on behalf of the iGenoMed Consortium. (2018) Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review. Canadian Journal of Gastroenterology and Hepatology 2018, pages 1-14.
Crossref
Gilaad G. Kaplan & Tine Jess. (2016) The Changing Landscape of Inflammatory Bowel Disease: East Meets West. Gastroenterology 150:1, pages 24-26.
Crossref
Dario Sorrentino, Marco Marino, Themistocles Dassopoulos, Dimitra Zarifi & Tiziana Del Bianco. (2015) Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab. PLOS ONE 10:12, pages e0144900.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.